EORTC

What EORTC does

EORTC (European Organisation for Research and Treatment of Cancer) is a Belgian AISBL non-profit founded in 1962 that coordinates and conducts multinational clinical cancer research from its Brussels headquarters. It operates through a network of 4,200+ investigators and clinicians across 74+ countries, currently managing 140+ active clinical studies with 33+ actively recruiting. Its core customers are academic medical centres, clinical researchers, and pharmaceutical/biotech companies seeking pan-European trial infrastructure; patients participate as trial subjects.

EORTC's technology and product portfolio centres on standardised cancer research infrastructure rather than commercial software. Flagship assets include the SPECTA platform (supporting biomarker programmes BioRadon, IMMUcan, and MRD for translational research), the E²-RADIATE infrastructure project (with OligoCare and ReCare radiation-research cohorts), RECIST (the standardised response-evaluation criteria widely adopted in solid tumour trials), and SISAQOL (patient-reported outcome measurement standards). These are not licence-based commercial products but shared research methodologies and coordination platforms. EORTC also maintains disease-specific investigator groups (Breast, Pathobiology, GI Tract Cancer, etc.) and high-visibility scientific convening through the annual ENA (EORTC-NCI-AACR) Symposium and the European Breast Cancer Conference (EBCC).

EORTC's revenue model is a hybrid of three streams: (1) recurring research grants and funding from government bodies, cancer societies, and pharmaceutical sponsors supporting specific trials; (2) annual membership dues from its 4,200+ member network; and (3) conference and event revenue from ENA, EBCC, and related meetings, with tiered registration pricing for academic (€295-1,240), industry (€1,025-2,040), and student/resident (€290-595) attendees. Strategic partnerships with the US National Cancer Institute (NCI), the American Association for Cancer Research (AACR), the European Thoracic Oncology Platform (ETOP), and the European Medical Agency (EMA) anchor its institutional position. EORTC does not publish revenue figures.

Name

EORTC

Legal name

EORTC AISBL

Website

https://eortc.org

Company type

Private

Founded year

1962

Operating status

Operating

Headcount range

251–500 employees

Short description

EORTC is a Belgian non-profit founded in 1962 that coordinates multinational cancer clinical trials across 74+ countries through a 4,200+ member investigator network, 140+ active studies, and standardised research platforms (SPECTA, E²-RADIATE, RECIST, SISAQOL), serving academic medical centres, researchers, and pharma sponsors.

Ownership category

akta.pro rank

Product category

Cancer Clinical Research

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Cancer clinical trials
• Oncology research coordination
• Biomarker research platforms
• Patient-reported outcomes
• Radiation therapy research

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Conference and Event Revenue: Registration fees from major conferences including ENA and EBCC
2. Research Grants and Funding: Funding from government bodies, cancer societies, and institutional supporters for clinical trials and research projects
3. Membership Dues: Network of 4200+ members contributing to organizational operations

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

EORTC designs, coordinates, and conducts multinational clinical trials in oncology through its network of 4,200+ researchers across 74+ countries. It operates standardized research infrastructure including the SPECTA biomarker platform, E²-RADIATE radiation therapy project, RECIST tumor response criteria, and SISAQOL patient-reported outcome standards. The organization also delivers annual scientific conferences (ENA and EBCC) and educational programs for the global cancer research community.

Product overview

EORTC (European Organisation for Research and Treatment of Cancer) is a clinical cancer research organization, not a product company. EORTC operates as a research infrastructure and coordination body that conducts multinational clinical trials, develops research platforms, and establishes standardized methodologies for cancer research. The organization's primary offerings include the SPECTA research platform (supporting biomarker research through programs like BioRadon, IMMUcan, and MRD), the E²-RADIATE infrastructure project (for radiation therapy research including OligoCare and ReCare cohorts), RECIST standardized response criteria for tumor assessment, and SISAQOL for patient-reported outcomes measurement. EORTC also organizes major scientific conferences including the ENA (EORTC-NCI-AACR) Symposium and EBCC (European Breast Cancer Conference). The organization provides clinical trial infrastructure, quality assurance, data sharing capabilities, and education and training programs to its network of 4200+ members across 74+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• SPECTA: A platform for coordinated cancer research infrastructure projects including BioRadon, IMMUcan, and MRD.
• E2-RADIATE
• RECIST
• SISAQOL
• ENA
• EBCC

Products and services

• SPECTA Platform Centralized biomarker research platform providing infrastructure for collaborative cancer research across multiple projects including BioRadon, IMMUcan, and MRD, enabling data and sample sharing for translational research studies.
• IMMUcan Cancer immunoprofiling research program within SPECTA for comprehensive immunological biomarker analysis in cancer patients.
• MRD (Minimal Residual Disease) Program Minimal Residual Disease research program within SPECTA focused on detecting and monitoring residual cancer after treatment.
• BioRadon Biobanking and radon research program within SPECTA for sample collection and biomarker discovery in cancer research.
• E²-RADIATE International infrastructure project for radiation therapy research enabling evidence-based treatment optimization across multiple cancer types, including OligoCare and ReCare cohorts.
• OligoCare Oligonucleotide therapeutics research cohort within E²-RADIATE focused on targeted cancer treatments.
• ReCare Rehabilitation and recovery research cohort within E²-RADIATE focused on patient outcomes after radiation therapy.
• RECIST Internationally recognized standardized criteria for evaluating tumor response in cancer clinical trials, widely adopted in oncology research.
• SISAQOL International set of standards for measuring and analyzing patient-reported outcomes in oncology clinical trials.
• ENA Symposium (EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics) Annual international scientific conference on molecular targets and cancer therapeutics, co-organized with the National Cancer Institute and the American Association for Cancer Research. ENA 2026 is accredited for European CME credits and compliant with EthicalMedTech standards.
• EBCC (European Breast Cancer Conference) Major multidisciplinary breast cancer meeting organized by EORTC Breast Group, presenting new research on breast cancer treatment and management.

Quantifiable outcome

• 140+ active clinical studies conducted simultaneously
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and flagship.

• National Cancer Institute (NCI)coreStrategic or Co-development PartnerCo-organizer of the annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. NCI provides scientific leadership and participates in joint conference committees.
• American Association for Cancer Research (AACR)coreStrategic or Co-development PartnerCo-organizer of the annual ENA Symposium. AACR co-chairs the symposium and provides scientific program oversight.
• ETOP (European Thoracic Oncology Platform)coreStrategic or Co-development PartnerCollaborative partnership for Phase III SPLENDOUR trial in non-small cell lung cancer, analyzing Platin-DRP biomarker data.
• SPECTA Platform PartnerscoreTechnology or IntegrationMulti-project research platform infrastructure supporting BioRadon, IMMUcan, and MRD projects for centralized cancer research coordination.
• EORTC Breast GroupcoreStrategic or Co-development PartnerSpecialized research group focused on breast cancer clinical trials and the EBCC conference series.
• European Medical Agency (EMA)flagshipStrategic or Co-development PartnerEORTC is a member of EMA's eligible healthcare professional organisations, contributing to regulatory discussions and drug approval processes.
• Oncoplastic Breast ConsortiumcoreStrategic or Co-development PartnerInternational research network bringing together breast surgeons and researchers for collaborative studies on breast reconstruction and treatment.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• IQVIA: Global commercial CRO and clinical trial services provider with a large oncology practice. Comparable as an alternative execution channel for the same pharma-sponsored oncology trials; competes with EORTC's academic coordination model on speed, scale, and global reach.
• National Cancer Institute (NCI): U.S. federal agency funding and coordinating large-scale cancer research. Comparable as a sponsor and coordinator of oncology clinical trials; EORTC co-organizes ENA with NCI and shares scientific committee roles.
• AACR (American Association for Cancer Research): Largest professional society for cancer research globally. Comparable as the co-organizer and scientific authority behind ENA; AACR sits in an overlapping space of cancer research dissemination and trial community convening.

Direct peers

• European Thoracic Oncology Platform (ETOP): European cooperative group focused on thoracic oncology trials. Direct peer in European academic oncology trial coordination; EORTC and ETOP co-conducted the SPLENDOUR Phase III lung cancer trial.
• SWOG Cancer Research Network: One of the largest U.S. NCI-supported cancer clinical trials cooperative groups. Direct peer to EORTC in coordinating multi-center oncology trials and competing for the same international pharma trial sponsorships.
• Alliance for Clinical Trials in Oncology: U.S. NCI-sponsored cooperative group running adult cancer clinical trials. Direct peer to EORTC in academic oncology trial design and execution, competing for the same pharma-sponsored studies.
• Breast International Group (BIG): International network coordinating breast cancer clinical trials across academic groups globally. Direct peer to EORTC's breast cancer research portfolio, including co-organized conferences such as EBCC.
• ECOG-ACRIN Cancer Research Group: Joint U.S. cooperative group formed from ECOG and ACRIN, conducting oncologic imaging and treatment trials. Direct peer to EORTC in academic oncology trial coordination, with comparable biomarker and translational research programs.
• NRG Oncology: U.S. National Cancer Institute-sponsored cooperative group running multi-modality oncology clinical trials. Direct peer to EORTC as a national/regional academic clinical trials network in oncology, competing for the same pharma-sponsored study pipeline.
• Canadian Cancer Trials Group (CCTG): Canadian cooperative oncology trials group, recently co-signed G7 cancer research commitments with EORTC. Direct peer as a national academic trials network collaborating on the same multinational oncology studies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/EORTC
• YouTubeyoutube.com/channel/UCNyJUbzB5U8hUDQ01j8LQoQ
• Facebookfacebook.com/EORTC
• LinkedInlinkedin.com/company/eortc
• Instagraminstagram.com/eortc_org

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EORTC